CONCLUSIONS

• Dose needed for Full ON not correlated with:
  - Baseline H & Y score (R²=6E-05)
  - Pre-Dose MDS-UPDRS Part III Score (R²=0.00005)
  - Baseline Levodopa Dose (R²=0.05000)

• # of Daily OFF Episodes (R²=0.05000)

• Disease severity did not predict the effective dose needed to turn an OFF patient to a Full ON state.

This data would support titrating patients from the lowest available dose.

• Phase 3 studies are ongoing to further evaluate efficacy and safety of APL-130277.

ACKNOWLEDGEMENTS/DISCLOSURES

This study was supported by Cynapsus Therapeutics. Additionally, the Michael J. Fox Foundation provided grant support for the study. EJF, AA, AS, and TB are employees of Cynapsus Therapeutics and hold stock or stock options. HS, SI and RAH were Investigators in the study and received compensation from Cynapsus for research and consultancy activities. APL-130277 is currently an investigational product.